JP2018115201A5 - - Google Patents

Download PDF

Info

Publication number
JP2018115201A5
JP2018115201A5 JP2018061990A JP2018061990A JP2018115201A5 JP 2018115201 A5 JP2018115201 A5 JP 2018115201A5 JP 2018061990 A JP2018061990 A JP 2018061990A JP 2018061990 A JP2018061990 A JP 2018061990A JP 2018115201 A5 JP2018115201 A5 JP 2018115201A5
Authority
JP
Japan
Prior art keywords
atoms
substituted
unsubstituted
unbranched
branched alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018061990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018115201A (ja
JP6763904B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018115201A publication Critical patent/JP2018115201A/ja
Publication of JP2018115201A5 publication Critical patent/JP2018115201A5/ja
Application granted granted Critical
Publication of JP6763904B2 publication Critical patent/JP6763904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018061990A 2011-05-23 2018-03-28 ピリジン−及びピラジン誘導体 Expired - Fee Related JP6763904B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488997P 2011-05-23 2011-05-23
US61/488,997 2011-05-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016124235A Division JP2016196492A (ja) 2011-05-23 2016-06-23 ピリジン−及びピラジン誘導体

Publications (3)

Publication Number Publication Date
JP2018115201A JP2018115201A (ja) 2018-07-26
JP2018115201A5 true JP2018115201A5 (enExample) 2020-08-13
JP6763904B2 JP6763904B2 (ja) 2020-09-30

Family

ID=45976540

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014512837A Expired - Fee Related JP6054954B2 (ja) 2011-05-23 2012-04-11 ピリジン−及びピラジン誘導体
JP2016124235A Pending JP2016196492A (ja) 2011-05-23 2016-06-23 ピリジン−及びピラジン誘導体
JP2018061990A Expired - Fee Related JP6763904B2 (ja) 2011-05-23 2018-03-28 ピリジン−及びピラジン誘導体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014512837A Expired - Fee Related JP6054954B2 (ja) 2011-05-23 2012-04-11 ピリジン−及びピラジン誘導体
JP2016124235A Pending JP2016196492A (ja) 2011-05-23 2016-06-23 ピリジン−及びピラジン誘導体

Country Status (22)

Country Link
US (1) US9273029B2 (enExample)
EP (1) EP2714677B1 (enExample)
JP (3) JP6054954B2 (enExample)
KR (1) KR101581522B1 (enExample)
CN (1) CN103748086B (enExample)
AU (1) AU2012259333B2 (enExample)
BR (1) BR112013029640A2 (enExample)
CA (1) CA2832605C (enExample)
DK (1) DK2714677T3 (enExample)
EA (1) EA023364B1 (enExample)
ES (1) ES2699256T3 (enExample)
HR (1) HRP20181884T1 (enExample)
IL (1) IL229528A (enExample)
LT (1) LT2714677T (enExample)
MX (1) MX352975B (enExample)
PL (1) PL2714677T3 (enExample)
PT (1) PT2714677T (enExample)
RS (1) RS58015B1 (enExample)
SG (1) SG194105A1 (enExample)
SI (1) SI2714677T1 (enExample)
WO (1) WO2012161877A1 (enExample)
ZA (1) ZA201307429B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029640A2 (pt) * 2011-05-23 2017-06-13 Merck Patent Gmbh derivados de piridina e pirazina
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
PT3030554T (pt) * 2013-08-07 2018-05-28 Merck Patent Gmbh Derivados de ureia de piperidina
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
EP3105225A1 (en) 2014-02-12 2016-12-21 iTeos Therapeutics Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
WO2015173764A1 (en) 2014-05-15 2015-11-19 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
JP6499282B2 (ja) 2014-09-26 2019-04-10 ギリアード サイエンシーズ, インコーポレイテッド Tank結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体
US9994547B2 (en) 2014-10-06 2018-06-12 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
JP6788583B2 (ja) 2014-10-22 2020-11-25 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 増殖性疾患を処置するためのチアゾリル含有化合物
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
JP6775516B2 (ja) 2015-03-17 2020-10-28 ファイザー・インク 新奇な3−インドール置換誘導体、医薬組成物、および使用方法
JP2018527336A (ja) 2015-08-10 2018-09-20 ファイザー・インク 3−インドール置換誘導体、医薬組成物、および使用方法
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
US10710980B2 (en) 2016-07-20 2020-07-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
PE20191788A1 (es) * 2017-04-27 2019-12-24 Ishihara Sangyo Kaisha Compuesto de n-(4-piridil)nicotinamida o sal del mismo
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Alk2阻害剤及びjak2阻害剤を含む併用療法
AU2021292484A1 (en) 2020-06-16 2023-01-19 Incyte Corporation ALK2 inhibitors for the treatment of anemia
WO2022077034A1 (en) * 2020-10-09 2022-04-14 Napa Therapeutics Ltd. Heteroaryl amide inhibitors of cd38
CN116099004B (zh) * 2022-12-30 2024-01-30 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗膀胱癌的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
JP2007524682A (ja) * 2004-02-12 2007-08-30 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体−5の調節物質としてのビピリジルアミド
TW200800203A (en) * 2006-03-08 2008-01-01 Astrazeneca Ab New use
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
WO2009030890A1 (en) 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
ES2921576T3 (es) * 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
US8198285B2 (en) * 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
BR112013029640A2 (pt) * 2011-05-23 2017-06-13 Merck Patent Gmbh derivados de piridina e pirazina

Similar Documents

Publication Publication Date Title
JP2018115201A5 (enExample)
JP2016196492A5 (enExample)
JP7169412B2 (ja) 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体
JP2019031560A5 (enExample)
JP2010532768A5 (enExample)
JP2018127459A5 (enExample)
JP2016506369A5 (enExample)
JP2016006118A5 (enExample)
JP2016530259A5 (enExample)
JP2016515560A5 (enExample)
JP2016056183A5 (enExample)
JP2016503797A5 (enExample)
JP2014518884A5 (enExample)
JP2016513660A5 (enExample)
JP2015511613A5 (enExample)
JP2015515961A5 (enExample)
JP2015508103A5 (enExample)
JP2015517574A5 (enExample)
JP2013544276A5 (enExample)
JP2007514773A5 (enExample)
JP2017501237A5 (enExample)
JP2020097596A5 (enExample)
JP2016531126A5 (enExample)
JP2016501185A5 (enExample)
JP2013502441A5 (enExample)